Please select the option that best describes you:
Topics:
Gynecologic Oncology • Ovarian Cancer
Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?
Would your recommendation change if the patient was platinum-resistant?
Answer from: at Community Practice
Of course
Sign in or Register to read more